--- title: "CJC-1295+Ipamorelin NO DAC 5mg/5mg" url: "https://lotuspeptide.com/peptide/cjc-1295-ipamorelin-no-dac" canonical: "https://lotuspeptide.com/peptide/cjc-1295-ipamorelin-no-dac" type: "product" brand: "LotusPeptide" currency: "USD" price_low: "40.00" price_high: "300.00" availability: "out of stock" ships_from: "United States" handling_time_business_days: 1 returns: "not accepted" replacements_and_refunds: "damaged or lost items" intended_use: "Laboratory research use only" image: "https://lotuspeptide.com/order/api/media/products/27.webp?size=full&v=1" updated: "2026-10-05" order_url: "https://lotuspeptide.com/order/p/27" synonyms: "CJC-1295 without DAC (modified GRF 1-29, Mod GRF 1-29) with ipamorelin" pubchem: "9831659 (ipamorelin); no PubChem record for CJC-1295 without DAC" written_by: "LotusPeptide research team" --- # CJC-1295+Ipamorelin NO DAC 5mg/5mg > This blend holds two synthetic peptides in one vial: CJC-1295 without DAC, a 29-residue analog of growth hormone-releasing hormone also called modified GRF (1-29), and ipamorelin, a five-residue growth hormone secretagogue. Neither peptide is in an FDA-approved drug, and no published study has tested the two together. ## Packs and prices - Availability: Out of stock | Pack | Price | Per vial | |---|---|---| | Single Vial | $40 | $40 | | 5-Pack (5 vials) | $175 | $35 | | 10-Pack (10 vials) | $300 | $30 | ## At a glance - Also known as: CJC-1295 without DAC (modified GRF 1-29, Mod GRF 1-29) with ipamorelin - PubChem CID: 9831659 (ipamorelin); no PubChem record for CJC-1295 without DAC - Availability: Out of stock - Ships from: United States - Intended use: Laboratory research use only - Page updated: 2026-10-05 Written by LotusPeptide research team. This blend holds two synthetic peptides in one vial: CJC-1295 without DAC, a 29-residue analog of growth hormone-releasing hormone also called modified GRF (1-29) [1], and ipamorelin, a five-residue growth hormone secretagogue. Neither peptide is in an FDA-approved drug, and no published study has tested the two together. ## What is in the vial Each vial is listed as 5 mg of CJC-1295 without DAC plus 5 mg of ipamorelin. The two peptides belong to different classes. CJC-1295 is an analog of human growth hormone-releasing factor (1-29), usually written hGRF(1-29) [2]. Ipamorelin is a pentapeptide from the growth hormone-releasing peptide series, which acts at a different receptor [3]. Ipamorelin's chemistry, literature and regulatory position are covered on its own page; this page deals with the CJC-1295 component and with what changes when two peptides share a vial. ## The CJC-1295 naming problem The name CJC-1295 is used for two different molecules. The original CJC-1295, described by ConjuChem in 2005, is a tetrasubstituted hGRF(1-29) with an extra C-terminal lysine that carries a maleimidopropionamide group [2]. In rats, this reactive group became bound to serum albumin [2]. Later papers call this version CJC-1295 with DAC, for Drug Affinity Complex [4] [1]. Human studies published under the name CJC-1295 concern the compound ConjuChem described, and a 2026 review found no controlled human studies of the version without DAC [1]. A second peptide has been sold under the same name. In a paper published in 2010, Norwegian analysts reported that a preparation submitted by police and customs contained a 29-residue peptide amide whose proposed sequence was consistent with a peptide then marketed as CJC-1295 [5]. A 29-residue peptide has no extra C-terminal lysine, so it cannot carry the albumin-binding group of the original compound. Forensic papers use the name modified GRF 1-29 [6], and the 2026 review states that modified GRF (1-29) is the peptide called CJC-1295 without DAC [1]. Anti-doping work lists CJC-1295 with and without DAC as separate substances [4]. ## How modified GRF (1-29) differs from native GRF Modified GRF (1-29) corresponds to residues 1 to 29 of the original compound, ending in a C-terminal amide and without the added lysine [2] [1]. PubChem has no record for the no-DAC peptide itself. The residue order comes from PubChem's record for the DAC compound (CID 91971820): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg. Compared with native human GRF(1-29) amide, the peptide in sermorelin, this sequence differs at four positions: D-alanine at 2, glutamine at 8, alanine at 15 and leucine at 27. Older laboratory studies looked at two of these sites. In porcine plasma, native GRF(1-29) amide was cut between residues 2 and 3 with a half-life of 13 minutes. Alanine at position 15 slightly slowed this, and a D-amino acid at position 2 prevented that cleavage [7]. These were in vitro plasma measurements on related analogs, not studies of this blend. ## Regulatory status Neither component is the active ingredient of an FDA-approved drug, and Drugs@FDA lists no application for either. FDA's page on bulk drug substances that may present significant safety risks lists ipamorelin acetate in category 2 for outsourcing facilities since September 29, 2023. The same page lists CJC-1295 among substances previously in category 2 whose nominations were withdrawn. FDA's note on CJC-1295 cites possible immunogenicity, difficulty with peptide-related impurities and characterization, and reported serious adverse events including increased heart rate and a systemic vasodilatory reaction. GRF analogs, CJC-1295 included, are prohibited in sport [5] [4]. The material sold here is not a medicine and is supplied for laboratory research use only. ## What is not known Almost everything specific to this product is unstudied. PubMed holds no study of modified GRF (1-29) and ipamorelin given together, in animals or people; records that mention both are reviews and analytical papers. There are no published pharmacology, safety or stability data for the two-peptide mixture, and whether the peptides affect each other's stability when stored in one vial has not been reported. Material sold under these names is also variable. Danish forensic chemists found glycine-extended versions of both modified GRF 1-29 and ipamorelin in seized products [6]. ## Quality testing and storage A mixture needs testing for each component, not just one purity figure. Mass spectrometry should find both peptides at their expected masses. It also tells the two CJC-1295 forms apart: PubChem gives the DAC form a molecular weight of 3647.2 g/mol, and the no-DAC peptide is lighter by the extra lysine and maleimidopropionyl group. LC-MS was the method used to characterize the 29-residue peptide in the Norwegian case [5], and it also catches glycine-extended variants [6]. HPLC should resolve both main peaks and report the purity of each and the measured ratio between them, which should match the 1:1 label. Net peptide content, counter-ions, water and the lot number belong on the certificate. Store the vial as stated on the certificate of analysis and product label, sealed, dry and protected from light. ## Questions ### Is the CJC-1295 in this blend the version with DAC? No. This blend contains CJC-1295 without DAC, also called modified GRF 1-29: a 29-residue peptide amide without the albumin-binding lysine of the original CJC-1295 [2] [1]. The two are different molecules with different masses. ### Why does a blend need a different certificate from a single peptide? Because two peptides share one vial. The certificate should confirm the identity of each by mass spectrometry, give an HPLC purity for each, and report the measured ratio of the two, so that a mislabeled or unbalanced mixture can be caught. A single overall purity number cannot show either problem. ### Has the combination of CJC-1295 and ipamorelin been studied? No study testing this pair was found in PubMed. Records that mention both peptides are reviews and analytical papers. ## References 1. [Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026.](https://pubmed.ncbi.nlm.nih.gov/42395176/) 2. [Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005.](https://pubmed.ncbi.nlm.nih.gov/15817669/) 3. [Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.](https://pubmed.ncbi.nlm.nih.gov/9849822/) 4. [Memdouh S, Gavrilović I, Ng K, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021.](https://pubmed.ncbi.nlm.nih.gov/34665524/) 5. [Henninge J, Pepaj M, Hullstein I, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010.](https://pubmed.ncbi.nlm.nih.gov/21204297/) 6. [Gajda PM, Holm NB, Hoej LJ, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal. 2019.](https://pubmed.ncbi.nlm.nih.gov/30136411/) 7. [Su CM, Jensen LR, Heimer EP, et al. In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma. Horm Metab Res. 1991.](https://pubmed.ncbi.nlm.nih.gov/1826667/) _This page summarises published laboratory research and cites its sources. It is not medical advice and makes no claim that the compound treats, cures or prevents any condition. LotusPeptide sells it for laboratory research use only._ ## Shipping and returns - Orders are processed and shipped within 1 business day. - Returns are not accepted. - Replacements and refunds are offered on damaged or lost items. ## Related products - [BPC-157+TB500 (Blend) 10mg](https://lotuspeptide.com/peptide/bpc-157-tb500-blend.md): from $35 - [GHK-Cu](https://lotuspeptide.com/peptide/ghk-cu.md): from $20 - [Retatrutide](https://lotuspeptide.com/peptide/retatrutide.md): from $25 --- For laboratory research use only. Not for human or veterinary use. Prices are in US dollars and can change without notice.